Claims for Patent: 7,040,485

Summary for Patent: 7,040,485

Title:	Method and apparatus for packaging a drug-device combination product
Abstract:	A package for a drug-device combination product includes an outer package including a first gas impermeable sheet and a second gas impermeable sheet hermetically sealed there to on three sides. A gas permeable header is attached to an unsealed side of the first sheet and sealed to the second sheet on two sides. The first and second gas impermeable sheets and the header form an interior and an opening communicating with the interior. A gas permeable inner package is disposed within the outer package. A product is sealed within the inner package. The inner package is placed within the outer package and a top end of the header is sealed to the second sheet. The outer package is then sealed by sealing the first gas impermeable sheet to the second gas impermeable sheet at a seal point below the point where the header attaches to the first sheet.
Inventor(s):	Gupta; Rainuka (Cambridge, MA), Dextradeur; Alan J. (Franklin, MA)
Assignee:	Codman & Shurtleff, Inc. (Raynham, MA)
Application Number:	11/174,115
Patent Claims:	1. A package for a drug-device combination product, comprising: an outer package comprising: a first gas impermeable sheet; a second gas impermeable sheet hermetically sealed on three sides with the first gas impermeable sheet; a gas permeable header disposed at an unsealed side of the first gas impermeable sheet and sealed to the second gas impermeable sheet on two sides; and wherein the first and the second gas impermeable sheets and the gas permeable header form an interior and an opening communicating with the interior; and a gas permeable inner package designed to hold said drug-device combination product and be disposed within the outer package. 2. The package of claim 1, wherein the gas permeable inner package is disposed only between the first and the second gas impermeable sheets. 3. The package of claim 1, wherein the gas permeable inner package is a blister tray. 4. The package of claim 1, wherein the gas permeable inner package is a pouch. 5. A package for a product, comprising: a product incorporated with a drug; a gas permeable inner package sized to contain the product; and an outer package comprising: a first sheet comprising: a gas impermeable section; and a gas permeable header disposed to a first side of the gas impermeable section; a second sheet being gas impermeable and hermetically sealed on three sides to the first sheet; and the first and the second sheets forming an interior and an opening communicating with the interior, wherein the inner package is disposed within the outer package. 6. The package of claim 5, wherein the gas permeable inner package is disposed only between the gas impermeable section of the first sheet and the second sheet. 7. The package of claim 5, wherein the gas permeable inner package is a blister tray. 8. The package of claim 5, wherein the gas permeable inner package is a pouch. 9. The package of claim 5, wherein the drug is selected from the group comprising antimicrobial agents, antiangiogenesis, antiproliferatives, and anti-inflammatorys. 10. The package of claim 9, wherein the antimicrobial agents are selected from the group comprising antibiotics, antiseptics, and disinfectants. 11. The package of claim 10, wherein the antibiotics are selected from the group comprising tetracyclines, penicillins, macrolides, rifampin, gentamicin, vancomycinclindamycin, azithromycin, enoxacin, and combinations thereof. 12. The package of claim 9, wherein the antimicrobial agent is at least one of Rifampicin and Clindamycin. 13. The package of claim 9, wherein the antiangiogenesis are selected from the group comprising angiostatin, thalidomide, CC-5013, bevacizumab, squalamine, endostatin, angiostatin, angiozyme, paclitaxel, doxorubicin, epirubicin, mitoxantrone, and cyclophosphamide. 14. The package of claim 9, wherein the antiproliferatives is at least one of Sirolimus and Paclitaxel. 15. The package of claim 9, wherein the anti-inflanimatorys are selected from the group comprising ibuprofen, ketoprofen, motrin, or naproxen.

Details for Patent 7,040,485

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2023-09-30